SLC2A1 and melanoma: Patients with higher proportions of CD3+ T-cells and CD3+CA9+ T-cells within the 20 μm distance to GLUT1+ melanoma cells had significantly longer progression-free survival (p = 0.0133 and p = 0.0378, respectively).